Business Wire

EXSCIENTIA

18.8.2021 13:02:10 CEST | Business Wire | Press release

Share
Bristol Myers Squibb Exercises Option to Develop Exscientia’s AI-designed, Immune-modulating Drug Candidate

Exscientia , a clinical-stage, artificial intelligence (AI)-driven pharmatech company, today announced that Bristol Myers Squibb has elected to in-license an immune-modulating drug candidate created by Exscientia. Exscientia has two active collaborations with Bristol Myers Squibb, which together focus on multiple therapeutic areas, including oncology and immunology. A significant expansion of the relationship was announced earlier this year.

The in-licensed candidate targets a critical immunological kinase that historically has proven difficult to target due to the need for a combination of potency, selectivity, and overall drug-like properties. To design a novel candidate that overcame these issues, Exscientia utilized its end-to-end platform to drive the discovery process, including AI-driven design, structural biology, chemistry, and pharmacology, as well as late-stage preclinical studies. Exscientia’s precision design approach focused on solving, in parallel, parameters important to overall therapeutic performance for the target, such as potency, selectivity, safety, and physicochemical characteristics. Exscientia’s platform is ideally suited for solving multi-objective design problems to efficiently and rapidly discover novel drug candidates with superior properties.

Andrew Hopkins, Chief Executive Officer of Exscientia commented, “We are focused on using our patient-first AI technology to design precision engineered drugs against challenging drug product profiles. We are seeing great efficiency from our platform. This drug candidate molecule was just the 150th novel compound to be designed and tested and it was identified within 11 months of starting drug design. In partnership with Bristol Myers Squibb and its world-class research, clinical and commercialization capabilities, we look forward to advancing this candidate into the next stage of development.”

Rupert Vessey, President of Research & Early Development at Bristol Myers Squibb said, “We are pleased to in-license our first drug candidate resulting from our strategic collaboration with Exscientia. Artificial intelligence and machine learning continue to play important roles in drug discovery and Exscientia has delivered a promising development candidate in the field of immunology. We look forward to our continued collaboration and further advancing this candidate for the potential benefit of patients with unmet medical need.”

Bristol Myers Squibb will be responsible for clinical and commercial development of the drug candidate. Under the terms of the agreement, Exscientia will receive a $20 million option exercise fee with the potential for additional development milestones as well as tiered royalties on any product sales.

About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created. Exscientia’s AI platform has now designed three drugs that are in Phase 1 human clinical trials.

Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.

Exscientia has offices in Oxford, Miami, Vienna, Osaka and Dundee. For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways to Participate in 9th Annual Evercore Healthcare Conference on December 119.11.2026 12:30:00 CET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 9th Annual Evercore Healthcare Conference on December 1, 2026 and will participate in a fireside chat at 3:25pm ET. A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/FkwyWrnNgoveMhBfJS2NCC/We7ydUWZPZM5Wf4zVRNZnZ A replay of the webcast will be accessible for 30 days following each event at the “Events” page of the Investors section of the Compass website. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation f

Pretium Expands Real Estate Debt Platform19.11.2026 12:00:00 CET | Press release

Addition of Hilltop Capital Partners Enables the Firm to Deploy Capital to the U.K. Housing Market Pretium, a specialized investment firm with approximately $70 billion in assets under management, today announced it is expanding its residential real estate debt platform, further enabling the flow of capital to real estate investors, developers and homebuilders. Since launching its residential debt platform in December 2024, Pretium has lent approximately $8 billion for the purpose of new housing construction and the renovation of existing homes. Building on its existing model, Pretium is adding the team from Hilltop Capital Partners (“Hilltop”), a specialized U.K.-based institutional capital advisor, investment manager and principal lender, to its vertically integrated residential real estate platform. Led by Paul Oberschneider and Tiger Craft, Hilltop has grown into a leading platform for residential development finance across the U.K since its founding in 2019. “The U.K. faces a hous

SRM and Ridgemont Equity Partners Announce Strategic Partnership to Accelerate Next Phase of Growth19.11.2026 12:00:00 CET | Press release

SRM and Ridgemont Continue a 30+ Year Track Record of Helping Banks, Credit Unions, and Fintech Companies Unlock Growth, Innovation, and Operational Efficiency Strategic Resource Management (SRM), a trusted, tech-enabled advisory firm serving financial institutions globally, today announced a strategic investment from Ridgemont Equity Partners, a middle market private equity investor. Building on over three decades of experience serving financial institutions and fintechs, this recapitalization aims to further strengthen SRM’s capabilities, talent, systems, and resources. Brad Downs, Chief Executive Officer and Chairman, and SRM’s existing leadership team will continue to lead the company into its next phase of growth. “SRM is a market-leading advisory firm with a strong reputation and proven track record, and is led by a very experienced executive team with a passion for delivering measurable results and meaningful business impact. SRM is an excellent fit with our experience in Busine

Healthcare Accelerates AI Investment as Governance and Risk Shape the Path to Value19.11.2026 10:26:00 CET | Press release

HTEC research finds 83% of healthcare and life sciences organizations have increased AI investment, yet adoption is still shaped by regulatory complexity, validation requirements, and organizational readiness HTEC, the global AI technology and engineering leader, today released new research examining how healthcare and life sciences organizations measure, track, and realize value from AI investments, as well as the risks and barriers preventing them from doing so at scale. The findings reveal that while investment continues to rise, organizations that successfully scale AI focus not only on technology, but also on the governance, workforce adoption, and operational foundations needed to track, prove, and realize impact. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119322683/en/ HTEC research finds 83% of healthcare and life sciences organizations have increased AI investment, yet adoption is still shaped by regulatory c

Logistics Reply Expands Robot-Assisted Fulfilment at The Quality Group19.11.2026 10:00:00 CET | Press release

Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has deepened its collaboration with The Quality Group (TQG) by implementing an agile intralogistics system for the company’s new fulfilment centre in Elsdorf, near Bremen. The project combines autonomous robotics with human expertise to help the site manage highly dynamic order volumes and process up to 100,000 orders per day across its 50,000-square-metre facility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119787784/en/ Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has deepened its collaboration with The Quality Group (TQG) by implementing an agile intralogistics system for the company’s new fulfilment centre in Elsdorf, near Bremen. The project combines autonomous robotics with human expertise to help the sit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye